Candel Therapeutics IPO

Developer of cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.

Total Funding to Date$67.6MM
Register for Details

For more details on financing and valuation for Candel Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Candel Therapeutics Ticker Symbol


Candel Therapeutics Stock Price

$1.83 as of 11/25/22